Sermorelin peptide vs tesamorelin: how the two compare

Last updated 2026-07-24

What are sermorelin and tesamorelin, exactly?

Both are synthetic peptides that mimic growth-hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland to release its own growth hormone. Neither is growth hormone itself. That distinction matters more than most marketing pages let on. Sermorelin is a 29-amino-acid fragment that corresponds to the biologically active end of natural human GHRH. It was studied for decades as a diagnostic and therapeutic agent and was FDA-approved under the brand name Geref for evaluating growth hormone deficiency in children ^[1]. Tesamorelin is a modified, longer-acting analog of GHRH (1-44), stabilized with a trans-3-hexenoic acid group so it resists breakdown in the body. It's sold under the brand name Egrifta (and Egrifta SV), and it has one specific FDA-approved indication: reducing excess visceral fat in HIV patients with lipodystrophy ^[1]. It is not approved for anti-aging use, muscle building, or general growth hormone deficiency in adults. So right away, the comparison isn't really "peptide A vs peptide B" in a vacuum. It's an off-label, compounded therapy versus an FDA-approved drug used almost entirely outside its approved population by people interested in body composition changes.

Is sermorelin FDA approved, and what happened to Geref?

Sermorelin was FDA approved. The brand Geref (sermorelin acetate) was cleared for diagnostic testing of growth hormone secretion and, in an injectable form, for treating growth hormone deficiency in children ^[1]. Geref was discontinued, not pulled for safety reasons. The manufacturer stopped marketing it for business reasons, a common outcome for older diagnostic drugs with small markets once patents lapse and cheaper alternatives exist. The FDA's own approval history for the product reflects a discontinuation of marketing rather than a safety-driven withdrawal ^[1]. That history is actually a point in sermorelin's favor compared to many peptides sold online today: it has real human clinical data behind it and a documented approval, even though that approval predates the modern peptide boom and isn't currently active. Today, sermorelin used clinically comes almost entirely from compounding pharmacies, filling prescriptions written off-label for adult patients with low IGF-1 or suspected growth hormone insufficiency. For a fuller regulatory and mechanism rundown, see sermorelin.

Is tesamorelin FDA approved, and for what?

Yes, tesamorelin (Egrifta) is FDA approved, and its approval is active and specific. It's indicated for reducing excess abdominal visceral fat in patients with HIV who have lipodystrophy, a condition where antiretroviral therapy causes abnormal fat redistribution ^[1]. The key trials behind that approval showed measurable reductions in visceral adipose tissue (VAT) over 26 weeks compared to placebo, using CT-scan-measured fat volume as the primary endpoint ^[2]. That's a harder, more objective endpoint than most peptide studies use. The FDA label is explicit about the limits of that approval. It does not extend to weight loss for people without HIV, cosmetic fat reduction, or performance enhancement. Using tesamorelin outside HIV-associated lipodystrophy is off-label, same as most sermorelin use, but tesamorelin at least has phase 3 trial data in humans supporting the effect it's approved for.

Sermorelin vs tesamorelin: how do they compare side by side?

Which one is more effective for raising growth hormone or IGF-1?

Both peptides raise growth hormone and downstream IGF-1 levels by stimulating the pituitary, but they aren't equally effective at that job. Tesamorelin's longer half-life (roughly 26 to 38 minutes versus sermorelin's 11 to 12 minutes) ^[2][3] gives it more sustained receptor stimulation per dose, and this shows up in its trial data as consistent IGF-1 increases alongside visceral fat reduction ^[2]. Sermorelin's shorter half-life means it clears fast. That's part of why it's usually dosed at night, to work with the body's natural GH pulse during sleep rather than trying to force a sustained elevation. For the specific outcome tesamorelin was studied for, visceral fat reduction in HIV lipodystrophy, it has stronger, more direct evidence. For general "raise my GH and IGF-1 modestly and safely" use, sermorelin has a longer, if older, track record and is the more common off-label choice. Neither peptide should be expected to produce dramatic increases; both are working with your own pituitary's ceiling, unlike injected HGH itself.

How does either peptide compare to taking HGH directly?

This is the question most readers actually want answered, and the honest answer is that neither sermorelin nor tesamorelin is a substitute for HGH if what you need is a large, reliable hormone increase. Injectable recombinant human growth hormone (somatropin) puts a fixed dose of the finished hormone directly into your body. It bypasses your pituitary entirely. GHRH analogs like sermorelin and tesamorelin only work if your pituitary still has functioning growth-hormone-producing cells to stimulate; they ask your body to make more of its own hormone, within its own natural pulsatile pattern and feedback limits. That difference cuts both ways. HGH gives a more predictable, dose-controlled increase, which is why it's the standard treatment for confirmed adult growth hormone deficiency diagnosed through stimulation testing (sermorelin itself has historically been used as one such test) ^[1]. But HGH also shuts down your own natural GH production over time through negative feedback, carries a real side effect profile (fluid retention, joint pain, insulin resistance, and carpal tunnel symptoms are documented in FDA-approved somatropin labeling) ^[1], and requires much closer monitoring. Sermorelin, by working through the pituitary, generally preserves the body's natural feedback loops, which is one reason its side effect profile tends to run milder. But that same mechanism means it simply won't work, or will work weakly, in someone whose pituitary is already significantly damaged or non-functional. If a prescriber's stimulation testing shows your pituitary can't respond, a GHRH analog isn't the right tool. That's a real limitation, more than a footnote. For most adults exploring these options without a diagnosed pituitary lesion or severe GH deficiency, GHRH peptides are the gentler, more conservative starting point precisely because they can't overshoot; your own pituitary still has the final say on how much hormone gets released.

How are sermorelin and tesamorelin dosed differently?

Sermorelin is typically dosed as a nightly subcutaneous injection, commonly in ranges around 200 to 500 micrograms for adults in off-label compounded protocols, though actual prescribed doses vary by prescriber and by the patient's weight and goals. Bedtime dosing lines up with the body's largest natural GH pulse, which happens during deep sleep. Tesamorelin's FDA label specifies a 1 mg subcutaneous injection once daily, reconstituted from lyophilized powder, injected into the abdomen ^[1]. Egrifta SV is a reformulated version requiring less reconstitution volume than the original Egrifta. Neither dose should be self-adjusted based on how peptides are typically described online. Actual titration depends on baseline IGF-1 levels, response after several weeks, and side effects like injection-site reaction or fluid retention. If you want a structured look at typical ranges and how prescribers think about titration, see the sermorelin dosage chart and the sermorelin dosage calculator.

What do the side effect profiles look like?

Sermorelin's most commonly reported side effects, from the diagnostic and pediatric literature behind Geref's approval, include injection site redness or pain, flushing, headache, and dizziness ^[1]. Serious adverse events were uncommon in the trials supporting its original approval. Tesamorelin's label lists injection site reactions (erythema, pruritus, pain) as the most common side effects in its phase 3 trials, along with arthralgia (joint pain), peripheral edema, and rare reports of hypersensitivity reactions ^[1]. Because it raises IGF-1, the label also carries a caution about worsening glucose tolerance, which matters more for the HIV population it was studied in, many of whom already have metabolic risk factors from antiretroviral therapy. Neither peptide has the kind of long-term (10+ year) safety data that would exist for a decades-old approved drug used at scale, because neither is used at that scale in the general population. For a longer look at what's known and not known about extended use, see sermorelin long-term side effects.

Which one is right for fat loss specifically?

If visceral fat reduction is genuinely the goal and you have HIV-associated lipodystrophy, tesamorelin is the peptide with an actual FDA approval and phase 3 trial data for that exact outcome ^[1][2]. That's not a close call. If you don't have HIV-associated lipodystrophy, you're looking at off-label use of either peptide, and neither has strong trial evidence for general fat loss in metabolically healthy adults. Sermorelin's supporting data is mostly about GH/IGF-1 stimulation and diagnostic use, not body composition outcomes in broad populations. Some smaller studies and off-label clinical experience suggest modest body composition shifts with either peptide over months of use. This is a much thinner evidence base than the approved-indication data, though. Reputable prescribers are usually candid that results are modest and slow, not the kind of change seen with caloric deficit and resistance training.

How do the costs and access routes compare?

Tesamorelin as brand-name Egrifta/Egrifta SV is expensive, often exceeding $1,500 a month at cash price before manufacturer assistance programs, reflecting its patent-protected, FDA-approved status for a narrow HIV indication ^[1]. Insurance typically only covers it for that labeled use. Sermorelin is compounded, not sold as an active FDA-approved brand today, and pricing is set by compounding pharmacies rather than a patent holder. Typical monthly costs for compounded sermorelin protocols often fall in a rough $150 to $300 range, though this varies widely by clinic, dose, and region, and compounded products aren't FDA-verified for potency and purity the way an approved brand-name drug is. That access gap is a real practical driver of why sermorelin is far more commonly discussed for off-label, general adult use: it's dramatically cheaper and more accessible through telehealth and compounding pharmacy networks than a $1,500-a-month specialty HIV drug would ever be for someone without that diagnosis.

Do compounding pharmacy quality and sourcing matter here?

Yes. And this is where sermorelin and tesamorelin diverge in an important, underappreciated way. Tesamorelin, when used as Egrifta, comes from a single FDA-regulated manufacturer with lot-level quality control. Sermorelin, since Geref's discontinuation, comes almost entirely from compounding pharmacies operating under state pharmacy boards and, for larger facilities, FDA's 503B outsourcing facility framework, a structure created by the Drug Quality and Security Act of 2013 ^[4]. Compounded sermorelin isn't individually FDA-approved as a finished product, which means potency, sterility, and purity depend heavily on which pharmacy fills the prescription. This is exactly why working with a provider who reviews your labs and prescribes through an established, quality-vetted pharmacy relationship matters more for sermorelin than it would for a standardized brand-name drug. Sermorelin Co's provider-reviewed process is built around exactly this gap, connecting patients to prescribers who then route prescriptions through a vetted fulfilling pharmacy partner rather than leaving sourcing to chance. For a look at what patients report about that process, see sermorelin reviews, and for how to find a legitimate local option, see sermorelin peptide near me.

Can you switch between sermorelin and tesamorelin, or use both?

There's no standard clinical protocol for combining sermorelin and tesamorelin, and doing so wouldn't make pharmacological sense for most patients: both work on the same GHRH receptor pathway, so stacking them is redundant rather than additive in the way combining drugs with different mechanisms might be. Switching from one to the other happens more often in practice, usually driven by cost, tolerability, or a change in goals (for example, a patient with diagnosed HIV lipodystrophy moving from general off-label sermorelin use to insurance-covered Egrifta once that diagnosis is confirmed). Any switch should go through the prescriber managing your labs and monitoring, not be self-directed, since dosing units and injection protocols differ meaningfully between the two.

Frequently asked questions

Is sermorelin the same thing as tesamorelin?

No. Both are GHRH analogs that stimulate the pituitary to release growth hormone, but they're chemically different molecules with different half-lives, different FDA histories, and different approved uses. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy; sermorelin was approved historically as Geref for diagnostic and pediatric use and is now used mainly off-label through compounding pharmacies.

Is tesamorelin stronger than sermorelin?

Tesamorelin has a longer half-life (roughly 26-38 minutes vs sermorelin's 11-12 minutes) and stronger, phase-3-trial-backed evidence for its approved use in visceral fat reduction. Whether that makes it "stronger" for other goals depends on the outcome in question; sermorelin's nightly dosing is designed to work with natural sleep-related GH pulses rather than sustain constant stimulation.

Why was Geref (sermorelin) discontinued?

Geref was discontinued for business and market reasons, not because of an FDA safety action. Older diagnostic drugs with small markets are frequently discontinued once patents expire and cheaper testing alternatives emerge. Its FDA approval record shows a marketing discontinuation rather than a safety-related withdrawal.

Can sermorelin replace HGH injections?

Not reliably for everyone. Sermorelin only works if your pituitary can still respond to GHRH stimulation; if a stimulation test shows a non-functional or severely damaged pituitary, sermorelin won't produce meaningful GH increases and direct HGH replacement is the appropriate option. For adults with a responsive pituitary and mild insufficiency, sermorelin is a gentler, feedback-preserving alternative, though the increase it produces is more modest than direct HGH dosing.

Is tesamorelin FDA approved for weight loss in general?

No. Tesamorelin (Egrifta/Egrifta SV) is FDA-approved specifically for reducing excess visceral abdominal fat in patients with HIV who have lipodystrophy. Any use for general weight loss, cosmetic fat reduction, or in patients without HIV-associated lipodystrophy is off-label and outside the studied population in its key trials.

How much does tesamorelin cost compared to sermorelin?

Brand-name tesamorelin (Egrifta) often costs $1,500 or more per month at cash price, reflecting its patented, FDA-approved status, though manufacturer assistance programs can lower out-of-pocket costs for eligible patients. Compounded sermorelin typically runs roughly $150 to $300 a month, though pricing varies by pharmacy, dose, and region.

Does insurance cover sermorelin or tesamorelin?

Tesamorelin may be covered by insurance when prescribed for its labeled indication, HIV-associated lipodystrophy, but is rarely covered for off-label use. Sermorelin, as a compounded (not currently branded) product used mostly off-label, is typically not covered by insurance and is usually paid out of pocket through a prescribing clinic or telehealth provider.

What are the main side effects of each peptide?

Sermorelin's most common reported effects include injection site redness, flushing, headache, and dizziness. Tesamorelin's label lists injection site reactions, joint pain (arthralgia), fluid retention, and a caution around glucose tolerance changes, since it raises IGF-1 meaningfully in a population that often already has metabolic risk factors.

Which peptide has better long-term safety data?

Neither has large-scale, decades-long safety data in general populations. Tesamorelin's phase 3 trials followed patients for about a year in the studies supporting FDA approval; sermorelin's data is largely older, from diagnostic and pediatric use, plus more recent but smaller off-label clinical experience. Long-term (multi-year) data for either in healthy adults using them off-label is genuinely thin.

Can you buy sermorelin or tesamorelin without a prescription?

Both are prescription-only in the United States. Tesamorelin is a prescription drug under its FDA approval. Sermorelin, though sold by some research-chemical sites without a prescription, should only be used under a prescriber's supervision with lab monitoring; unsupervised sourcing carries real quality and legal risk since it isn't dispensed as an FDA-approved finished product.

Do sermorelin and tesamorelin require the same injection technique?

Both are given as subcutaneous injections, typically in the abdomen, but tesamorelin (Egrifta) requires reconstitution from a lyophilized powder using specific diluent volumes per its FDA label, while sermorelin protocols vary by compounding pharmacy and may come pre-mixed or require simpler reconstitution. Always follow the specific instructions from the prescribing pharmacy, since volumes differ.

Is one of these peptides better for athletes or bodybuilders?

Neither is FDA-approved or well-studied for athletic or bodybuilding performance, and using either for that purpose is off-label with limited controlled evidence. Both are also included on the World Anti-Doping Agency's prohibited list for competitive athletes as growth hormone releasing peptides, so anyone in tested sport should assume either use carries a doping risk regardless of the marketing framing.

Sources

1. U.S. Food and Drug Administration, Drugs@FDA: Geref (sermorelin acetate) approval history, NDA 019810: Sermorelin was FDA-approved as Geref for diagnostic and pediatric growth hormone deficiency use and was later discontinued for marketing reasons
2. Falutz J, et al. "Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two randomized, double-blind, placebo-controlled phase 3 trials." PubMed PMID 20543730: Tesamorelin's pivotal trials showed CT-measured visceral adipose tissue reduction over 26 weeks versus placebo
3. Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. PubMed PMID 10993234: Sermorelin has a short plasma half-life of approximately 11 to 12 minutes
4. U.S. Food and Drug Administration, "Drug Quality and Security Act (DQSA), Public Law 113-54": Compounded drugs like sermorelin are produced under state pharmacy board or 503B outsourcing facility oversight established by the Drug Quality and Security Act rather than individual FDA product approval
5. World Anti-Doping Agency, 2024 Prohibited List: GHRH analogs including sermorelin and tesamorelin are included on the WADA prohibited substances list for competitive athletes
6. ClinicalTrials.gov, "Safety and Efficacy of Tesamorelin in HIV-Infected Patients With Excess Abdominal Fat," NCT00421551: Tesamorelin's phase 3 trial program studied HIV patients with excess abdominal fat over roughly a year of follow-up